These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 4598611)

  • 1. Variables influencing susceptibility testing of Cryptococcus neoformans to 5-fluorocytosine.
    Block ER; Jennings AE; Bennett JE
    Antimicrob Agents Chemother; 1973 Oct; 4(4):392-5. PubMed ID: 4598611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-fluorocytosine resistance in Cryptococcus neoformans.
    Block ER; Jennings AE; Bennett JE
    Antimicrob Agents Chemother; 1973 Jun; 3(6):649-56. PubMed ID: 4597734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined in vitro activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans and Candida albicans.
    Chen HH; Liushih RN; Hsieh WC
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1982 May; 15(2):106-12. PubMed ID: 7047097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Fluorocytosine resistance in clinical isolates of Cryptococcus neoformans.
    Chin CS; Cheong YM; Wong YH
    Med J Malaysia; 1989 Sep; 44(3):194-8. PubMed ID: 2696871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
    Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
    J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assay for yeast susceptibility to 5-fluorocytosine and amphotericin B in a frozen microtiter system.
    Ellis NS; Bartlett MS; Smith JW
    Am J Clin Pathol; 1979 Aug; 72(2):194-8. PubMed ID: 382827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cryptococcus neoformans: comparisons of in vitro antifungal susceptibilities of serotypes AD and BC.
    Fromtling RA; Abruzzo GK; Bulmer GS
    Mycopathologia; 1986 Apr; 94(1):27-30. PubMed ID: 3014339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibility of Cryptococcus gattii clinical isolates.
    Gomez-Lopez A; Zaragoza O; Dos Anjos Martins M; Melhem MC; Rodriguez-Tudela JL; Cuenca-Estrella M
    Clin Microbiol Infect; 2008 Jul; 14(7):727-30. PubMed ID: 18558948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy.
    Warnock DW; Johnson EM; Rogers TR
    J Antimicrob Chemother; 1998 Sep; 42(3):321-31. PubMed ID: 9786472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro susceptibility of Cryptococcus neoformans isolates from patients with acquired immunodeficiency syndrome.
    Poon M; Cronin DC; Wormser GP; Bottone EJ
    Arch Pathol Lab Med; 1988 Feb; 112(2):161-2. PubMed ID: 3276290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
    Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
    Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifungal activity of 5-fluorocytosine as measured by disk diffusion susceptibility testing.
    Utz CJ; Shadomy S
    J Infect Dis; 1977 Jun; 135(6):970-4. PubMed ID: 325150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo in mice.
    Hamilton JD; Elliott DM
    J Infect Dis; 1975 Feb; 131(2):129-37. PubMed ID: 1090685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifungal drug combinations for Cryptococcus neoformans and Prototheca spp.
    Srimuang S; Prariyachatigul C; Chaiprasert A; Rungsipanuratn W; Tanphaichitra D
    J Med Assoc Thai; 2000 Jan; 83(1):57-60. PubMed ID: 10710870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antimycotic activity in vitro and in vivo of 5-fluorocytosine on pathogenic strains of Candida albicans and Cryptococcus neoformans].
    Costa AL; Valenti A; Costa G; Calogero F
    G Batteriol Virol Immunol; 1976; 69(7-12):244-9. PubMed ID: 800772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A simple medium for 5-fluorocytosine sensitiving testing (author's transl)].
    Böhm W
    Dermatol Monatsschr; 1982 May; 168(5):317-20. PubMed ID: 7049776
    [No Abstract]   [Full Text] [Related]  

  • 17. Susceptibility of coccidioides immitis, Candida albicans, and Cryptococcus neoformans to amphotericin B, flucytosine, and clotrimazole.
    Hoeprich PD; Huston AC
    J Infect Dis; 1975 Aug; 132(2):133-41. PubMed ID: 1099147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of 5-fluorocytosine against Candida and Torulopsis species.
    Shadomy S; Kirchoff CB; Ingroff AE
    Antimicrob Agents Chemother; 1973 Jan; 3(1):9-14. PubMed ID: 4799552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flucytosine primary resistance in Candida species and Cryptococcus neoformans.
    Cuenca-Estrella M; Díaz-Guerra TM; Mellado E; Rodríguez-Tudela JL
    Eur J Clin Microbiol Infect Dis; 2001 Apr; 20(4):276-9. PubMed ID: 11399020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.
    Pfaller M; Zhang J; Messer S; Tumberland M; Mbidde E; Jessup C; Ghannoum M
    Diagn Microbiol Infect Dis; 1998 Nov; 32(3):191-9. PubMed ID: 9884835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.